Condition: Persistent Corneal Epithelial Defect · Sponsor: Dompé Farmaceutici S.p.A
This is a phase 3, randomized, multicenter, double-masked, parallel group, vehicle-controlled prospective clinical trial to evaluate the safety and efficacy of cenegermin in inducing complete epithelial healing in participants with PCED. The primary objective is the evaluation of complete epithelial healing after 4 weeks of treatment. The study is comprised of 3 periods: an 8-week initial treatment period (Day 1 to Week 8), an 8-week extension treatment period (Week 9 to Week 16), and a 24-week follow-up period (Week 17 to Week 40).
This description comes directly from the study's public registry record.
Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI) · +39 02 583 831
Always discuss trial participation with your own doctor first.
| Azul Vision, INC | Huntington Beach, California, United States | Recruiting |
| Harvard Eye Associates | Laguna Hills, California, United States | Recruiting |
| Loma Linda University Adventist Health Sciences Center | Loma Linda, California, United States | Not Yet Recruiting |
| UCLA - Jules Stein Eye Institute (JSEI) - Diabetic Eye Dise | Los Angeles, California, United States | Not Yet Recruiting |
| California Eye Specialists Medical Group, Inc. | Redlands, California, United States | Recruiting |
| East Coast Institute for Research - Florida Eye Specialists | Jacksonville, Florida, United States | Recruiting |
| Bascom Palmer Eye Institute, University of Miami School of Medicine | Miami, Florida, United States | Recruiting |
| University of South Florida | Tampa, Florida, United States | Recruiting |
| Massachusetts Eye and Ear | Boston, Massachusetts, United States | Recruiting |
| Ophthalmic Consultants of Boston | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Health - Kellogg Eye Center | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| Midwest Vision Research Foundation | Chesterfield, Missouri, United States | Recruiting |
+ 65 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07519902